EHA 2021 | INDEPENDENCE: luspatercept vs placebo in MPNs-associated myelofibrosis
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses updates on the INDEPENDENCE trial (NCT04717414) investigating the safety and efficacy of luspatercept versus placebo in patients with myeloproliferative neoplasm (MPNs)-associated myelofibrosis who are also red cell transfusion-dependent and receiving a concomitant Janus-kinase 2 (JAK2) inhibitor. The Phase III double-blind, randomised trial is ongoing and aims to add to the growing evidence that JAK inhibitors can help with common anemia in patients with myelofibrosis. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Ruben Mesa, MD, has participated in a consultancy role with Novartis, Sierra Onc, LaJolla, Pharma and Constellation; and has received research support from Celgene, Incyte, Abbvie, Samus, Genotech, Promedior, CTI and Constellation.
